A 2:1 formulation of follitropin alfa and lutropin alfa in routine clinical practice: A large, multicentre, observational study

Gynecological Endocrinology

Volumn 27, Issue 9, 2011, Pages 650-654

  Bühler, Klaus ^a   Naether, Olaf ^b  

^a Centre for Reproductive Medicine and Gynaecological Endocrinology   (Germany)

^b Fertility Center Hamburg   (Germany)

Author keywords

Assisted reproductive technology; follitropin alfa; hypogonadotrophic hypogonadism; lutropin alfa; ovarian stimulation

Indexed keywords

ESTROGEN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE; ORAL CONTRACEPTIVE AGENT; RECOMBINANT FOLLITROPIN PLUS RECOMBINANT LUTEINIZING HORMONE;

ADULT; ARTICLE; ASSISTED REPRODUCTIVE TECHNOLOGY; CLINICAL PRACTICE; CONGENITAL DISORDER; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG UTILIZATION; ECTOPIC PREGNANCY; EMBRYO TRANSFER; ESTROGEN BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MATERNAL AGE; MEDICAL TECHNOLOGY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; OOCYTE RETRIEVAL; OVARY HYPERSTIMULATION; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; POSTMARKETING SURVEILLANCE; PREGNANCY OUTCOME; PREGNANCY RATE; PRESCRIPTION; PRIORITY JOURNAL; REPRODUCTIVE PROCEDURES; SINGLE DRUG DOSE; SPONTANEOUS ABORTION; TREATMENT RESPONSE;

ADULT; FEMALE; FOLLICLE STIMULATING HORMONE, HUMAN; HUMANS; LUTEINIZING HORMONE; OVULATION INDUCTION; PRODUCT SURVEILLANCE, POSTMARKETING; RECOMBINANT PROTEINS;

EID: 80051505259     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2010.511014     Document Type: Article

References (16)

1. Chappel SC, Howles C. Reevaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process. Hum Reprod 1991;6:1206-1212.
2. Burgues S. The effectiveness and safety of recombinant human LH to support follicular development induced by recombinant human FSH in WHO group I anovulation: evidence from a multicentre study in Spain. Hum Reprod 2001;16:2525-2532. (Pubitemid 34007466)
3. Kaufmann R, Dunn R, Vaughn T, Hughes G, O'Brien F, Hemsey G, Thomson B, O'Dea LS. Recombinant human luteinizing hormone, lutropin alfa, for the induction of follicular development and pregnancy in profoundly gonadotrophin-deficient women. Clin Endocrinol (Oxf) 2007;67: 563-569. (Pubitemid 47416315)
4. Shoham Z, Smith H, Yeko T, O'Brien F, Hemsey G, O'Dea L. Recombinant LH (lutropin alfa) for the treatment of hypogonadotrophic women with profound LH deficiency: a randomized, double-blind, placebo-controlled, proof-of-efficacy study. Clin Endocrinol (Oxf) 2008;69:471-478.
5. The European Recombinant Human LH Study Group. Recombinant human luteinizing hormone (LH) to support recombinant human follicle-stimulating hormone (FSH)- induced follicular development in LH- and FSH-deficient anovulatory women: a dose-finding study. J Clin Endocrinol Metab 1998;83:1507-1514.
6. Bassett R, Lispi M, Ceccarelli D, Grimaldi L, Mancinelli M, Martelli F, Dorsselaer A. Analytical identification of additional impurities in urinary-derived gonadotrophins. Reprod Biomed Online 2009;19:300-313.
7. Agostinetto R. Administration of follitropin alfa and lutropin alfa combined in a single injection: a feasibility assessment. Reprod Biol Endocrinol 2009;7:48.
8. Alper M, Meyer R, Dekkers C, Ezcurra D, Schertz J, Kelly E. Assessment of the biopotency of follitropin alfa and lutropin alfa combined in one injection: a comparative trial in Sprague- Dawley rats. Reprod Biol Endocrinol 2008;6:31.
9. le Cotonnec JY, Loumaye E, Porchet HC, Beltrami V, Munafo A. Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone. Fertil Steril 1998;69:201-209. (Pubitemid 28117094)
10. Picard M, Rossier C, Papasouliotis O, Lugan I. Bioequivalence of recombinant human FSH and recombinant human LH in a fixed 2:1 combination: two phase I, randomised, crossover studies. Curr Med Res Opin 2008;24:1199-1208. (Pubitemid 351579179)
11. Alviggi C, Mollo A, Clarizia R, De Placido G. Exploiting LH in ovarian stimulation. Reprod Biomed Online 2006;12: 221-233. (Pubitemid 43263337)
12. Humaidan P, Bungum M, Bungum L, Yding Andersen C. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist downregulation and stimulation with recombinant FSH: an opening study. Reprod Biomed Online 2004;8:635-643. (Pubitemid 38744939)
13. O'Dea L, O'Brien F, Currie K, Hemsey G. Follicular development induced by recombinant luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in anovulatory women with LH and FSH deficiency: evidence of a threshold effect. Curr Med Res Opin 2008;24:2785-2793.
14. Pak SJ, Warlich J, van Rooij TN. [RecDate - an IT-solution for the documentation and quality management of reproductive medicine]. Zentralbl Gynakol 2001;123:482-486. (Pubitemid 32896288)
15. Nyboe Andersen A, Goossens V, Bhattacharya S, Ferraretti AP, Kupka MS, de Mouzon J, Nygren KG. Assisted reproductive technology and intrauterine inseminations in Europe, 2005: results generated from European registers by ESHRE: ESHRE. The European IVF Monitoring Programme (EIM), for the European Society of Human Reproduction and Embryology (ESHRE). Hum Reprod 2009;24:1267-1287.
16. German IVF Registry. Annual Report 2007. http://www.ftl.meb.uni-bonn.de/ frauen/DIR-downloads/dirjahrbuch2007.pdf. Last Accessed 22 September 2009.